The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

In July, the FDA issued a complete response letter (CRL) for Replimune's biologics license application for RP1 (vusolimogene ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...

In this segment, Dr Luskin examines how patient-related factors influence treatment decisions in blastic plasmacytoid ...

Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are ...

Dr Benjamin George champions innovative oncology care in rural Nebraska, emphasizing collaboration and multidisciplinary ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...

Dr Benjamin George transforms oncology care in rural Nebraska, addressing unique challenges and enhancing access to vital ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...